You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
After a study showed that patients who received guidance from Perthera's tumor board lived longer than those who didn't, the company wants to make its technology more accessible.
The company's FGFR inhibitor infigratinib is being evaluated in solid tumors and urothelial cancer.
The companies initially plan to validate biomarkers for use with the Oncomine Dx Target Test to identify NSCLC patients for enrollment into clinical trials.
Researchers found that more than 3 percent of postmenopausal women with breast cancer but no other disease risk factors carried pathogenic variants.
The study suggested that ALL glucocorticoid resistance stemming from alterations that drive down CELSR2 levels might be combated with the BCL2-targeting drug venetoclax.
The precision oncology startup is gearing up to enroll patients in its tissue-agnostic Phase I/II trial for its investigational new drug BDTX-189.
The FDA had previously approved neratinib as an extended adjuvant therapy for patients with early-stage HER2-overexpressed or amplified breast cancer, following adjuvant treatment with trastuzumab.
The study showed that patients with targetable genomic markers, especially HER2 alterations, responded well to chemotherapy-free treatments.
With EMR upgrades, Penn and Rush now have structured genomic data informing clinical decision support in their precision oncology programs, but much work remains.
A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.